Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia

Preeclampsia Postpartum Clinical Trial

Official title:

Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05937841
• Other study ID #: 202303202
• Status: Recruiting
• Phase: Early Phase 1
• Start date: June 28, 2023
• Est. completion date: June 1, 2025

Study information

• Verified date: July 2023
• Source: University of Iowa
• Contact: Kelsey Schwartz
• Phone: 319-467-3096
• Email: kelsey-schwartz[@]uiowa.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women.

The purpose of this study is to examine the microvascular differences in women who have had preeclampsia following activation of protective angiotensin receptors in the skin. This will help increase understanding of the mechanisms of angiotensin II receptors in these women, and how activation of these receptors may restore microvascular function.

In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: June 1, 2025
• Est. primary completion date: June 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• women who had preeclampsia and women who did not have preeclampsia

• 12 weeks to 5 years postpartum

• 18-45 years old

Exclusion Criteria:

• history of hypertension or metabolic disease before pregnancy

• history of gestational diabetes

• skin diseases

• current tobacco use

• current antihypertensive medication

• statin or other cholesterol-lowering medication

• currently pregnant or planning to become pregnant

• body mass index less than 18.5 kg/m2

• allergy to materials used during the experiment.(e.g. latex),

• known allergy to study drugs

Related Conditions & MeSH terms

• Pre-Eclampsia
• Preeclampsia Postpartum

Intervention

Drug:
• Compound 21
AT2R sensitivity: compound 21, and compound 21+ L-NAME (nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess AT2R-mediated dilation and role of nitric oxide in this response Local heating: compound 21 is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response

Locations

Country	Name	City	State
United States	University of Iowa	Iowa City	Iowa

Sponsors (1)

Lead Sponsor	Collaborator
Anna Stanhewicz, PhD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in microvascular blood flow response to local compound 21 treatment measured by laser-Doppler flowmetry	Cutaneous vascular vasodilator response (cutaneous conductance; %max) to exogenous compound 21 perfusion; intradermal microdialysis for the local delivery of compound 21	post 1 hour of skin perfusion
Primary	Change in microvascular endothelial function following local C21 treatment compared to placebo treatment measured by laser-Doppler flowmetry	Cutaneous vascular vasodilator response (cutaneous conductance; %max) to local heating of the skin; intradermal microdialysis for the local delivery of compound 21 compared to control (Ringer's solution), followed by L-NAME infusion to quantify NO-dependent response	post 1 hour of skin perfusion
Secondary	Angiotensin receptor expression in endothelial cells	Quantify expression of angiotensin II receptor expression in biopsied endothelial cells	a total of 1 time during the study, within ~4 weeks following enrollment